AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today the launch of Inform™Thyroid, a panel of molecular markers used on Fine Needle Aspirates (FNA) of thyroid nodules to aid physicians in the management of thyroid cancer. The FNAs are analyzed in Asuragen’s CAP accredited CLIA Laboratory. The Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer has stated, “The use of molecular markers (e.g., BRAF, RAS, RET/PTC, Pax8-PPARy) may be considered for patients with indeterminate cytology on FNA to help guide management.”
